Physician profile
Sara Khaled
NPI 1962077024
$1,621.40
in general payments reported to CMS, 2019-2025
20 companies · $177 in 2025
The $177 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $64.30 · 2022: $865 · 2023: $516 · 2025: $177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $692.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $692.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $712.09 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $197.44 | 2021-2023 | Xifaxan |
| Mallinckrodt Hospital Products INC. | $93.56 | 2022-2023 | Terlivaz |
| Dynavax Technologies Corporation | $88.95 | 2022-2023 | Heplisav-B |
| Genzyme Corporation | $60.11 | 2022-2023 | |
| Exact Sciences Corporation | $53.65 | 2023-2025 | Cologuard Collection Kit |
| Regeneron Healthcare Solutions, INC. | $52.75 | 2023 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $47.83 | 2022-2023 | Entyvio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $38.18 | 2025 | Caplyta |
| Ferring Pharmaceuticals INC. | $38.05 | 2022-2023 | Rebyota |
| Intercept Pharmaceuticals, INC. | $35.58 | 2023 | Ocaliva |
| W. L. Gore & Associates, INC. | $28.96 | 2021-2022 | |
| Ethicon US, LLC | $26.12 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $25.43 | 2023 | Bylvay |
| Renalytix Ai, INC. | $24.79 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $22.12 | 2023 | Ibsrela |
| Almatica Pharma LLC | $20.73 | 2025 | Loreev Xr |
| Redhill Biopharma INC. | $19.42 | 2023 | |
| Novo Nordisk INC | $18.42 | 2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $17.22 | 2025 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Khaled listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.